Uterine-Targeted Delivery of Dual Action Therapy for Preventing Preterm Birth

黄体酮目前是预防早产的主要疗法。不幸的是，许多女性对黄体酮的松弛作用不敏感。我们发现了一种双重作用剂，它(1)将子宫孕酮受体的表达维持在与孕酮敏感性一致的状态，(2)直接抑制子宫收缩。这种药剂有可能增加对黄体酮有反应的女性的比例，同时作为宫缩松解剂发挥“双重作用”。

Progesterone is currently a leading therapy for preventing preterm birth. Unfortunately, many women are insensitive to the relaxatory effects of progesterone. We discovered a dual-action agent that (1) maintains uterine progesterone receptor expression in a state that is consistent with progesterone sensitivity, and (2) directly inhibits uterine contractions. This agent has potential to increase the percentage of women that respond to progesterone, while exerting 'dual action' as a tocolytic.